Adbry

Generic Name: tralokinumab-ldrm

What is Adbry?

• Adbry is a prescription medication for adults suffering from moderate-to-severe atopic skin dermatitis (eczema) that isn’t effectively controlled by prescription treatments applied to the face (topical) or can’t use topical therapies. Adbry is a treatment that can be taken in conjunction with or without corticosteroids applied to the skin.
• It isn’t known whether Adbry is secure and effective for children.

Who is not a good candidate?

Don’t use Adbry in the event that you are allergic to tralokinumab or any of the other ingredients. Look at the end on this page to find an exhaustive listing of the ingredients.

Before making use of this medication

Before beginning treatment, inform your doctor about your medical condition and conditions, such as if:

• Have eye problems.
• are suffering from an infection that is infection that is parasitic (helminth) disease.
• Are planned to undergo any vaccines. It is not recommended to receive a “live vaccine” if you are being treated for Adbry.
• Are pregnant or planning to be pregnant or plan to. It’s unclear if Adbry could cause harm to your baby.
• Are breastfeeding or plan to breastfeed or plan. It’s unclear if Adbry is absorbed into breast milk, and if it could harm your baby.¶

What other medications can have an effect?

Talk to your doctor about any medications you are taking that you are taking, including prescription and non-prescription supplements as well as vitamins and herbal supplements.

How can I use it?

• Check out the comprehensive Instructions for the use that come with your prescription for details about how to make the injection of Adbry and the best way to keep and dispose of (dispose of out) used Adbry Syringes that are prefilled.
• Make sure you use this medication as directed by your doctor.
• Your physician will inform you of the amount of Adbry is to be injected and the best time to inject it.
• This is a single dose (150 mg) prefilled syringe, which comes with a needle guard.
• This medication is administered by injection into the skin (subcutaneous injection).
• If your healthcare provider determines that you or your caregiver should administer injections, either you or the caregiver should be given instruction on how for preparing and injecting Adbry. Don’t attempt injecting Adbry before you’ve been taught the correct way to inject it by your health care provider.
• If you do not take your dose, administer the dose missed as quickly as you can. Then, take your next dose at your regular time.
• In the event that you take more Adbry than the recommended dosage, call Poison Control at 1-800-222-1222.
• Your healthcare provider might prescribe additional medicines to be used in conjunction with Adbry. Take the prescribed medications precisely as your doctor advises you to.

Dosage information

Usual Adult Dosage for Atopic Dermatitis

• The initial dose is 600 mg (four 150 mg injections) and then 300 mg (two 150 mg injections) given every two weeks. A dose of 300 mg once every 4 weeks is possible for patients who weigh less than 100 kilograms and attain a clear or clean complexion after approximately 16 weeks.
• Treatment of moderate-to-severe allergic dermatitis in adults whose condition is not sufficiently controlled by topical prescription therapies, or when these therapies aren’t advised.¶

Preparation to Use

• Remove ADBRY prefilled syringes from the refrigerator and let them come to room temperature (30 minutes for the 150 mg/mL prefilled syringes) without removing the needle cap before injecting.
• Prefilled syringes can be maintained at room temperature up to 30°C (86°F) after being removed from the refrigerator, but they must be used within 14 days or discarded.
• Prior to administration, visually inspect ADBRY for particle debris and discoloration. ADBRY injection is a colorless to pale yellow, transparent to the opalescent solution. If the liquid contains visible particle matter, is discolored, or is hazy, do not use it (other than clear to opalescent, colorless to pale yellow).
• Because it contains no preservatives, any unused product should be discarded

Important Administrative Requirements

• It should only be used under the supervision of a healthcare professional. After receiving training in the subcutaneous injection method, a patient can self-inject ADBRY. Patients and/or caregivers should receive proper instruction on how to prepare and administer medications according to the “Instructions for Use.”
• Each of the four ADBRY 150 mg injections should be given at different injection locations within the same body area for the initial 600 mg dose.
• Administer the two ADBRY 150 mg injections at different injection locations within the same body area for the subsequent 300 mg dosages.
• Except for the 2 inches (5 cm) around the navel, inject subcutaneously into the thigh or abdomen. If the injection is given by a caregiver, the upper arm can also be used.
• With each succeeding batch of injections, rotate the body area. ADBRY should not be injected into delicate, injured, bruised, or scarred skin.

Adbry side effects

This medicaine can have severe side effects, which include:

• Allergy reactions (hypersensitivity) This includes an extreme reaction, called anaphylaxis. Stop taking Adbry and consult your physician or seek immediate medical attention when you experience any of the symptoms below:
  • breathing issues
  • chest pain
  • swelling of the mouth, face, and tongue
  • Hives
  • Itching
  • fainting or dizzy, feeling lightheaded (low blood pressure)
  • the skin the rash
• Eye issues. Inform your doctor when you are experiencing any more severe eyes problems, like eyes pain or changes in vision.

The most commonly reported adverse effects are:

• eyelid and eyelid inflammation such as swelling, redness, and itching
• injection site reactions
• high count of a particular number of white blood cells (eosinophilia)

This is not the only list of the possible adverse consequences. Consult your physician to seek medical advice on possible side effects. You can report any symptoms to FDA by calling 800-FDA-1088.

General information on the safety

Some medicines are used for reasons other than those stated in the Patient Information leaflet. Use this medicine only to treat a health condition for which it was not recommended. Don’t give it to others regardless of whether they are suffering from similar symptoms to yours. It could harm them. It is possible to ask your doctor or pharmacist for advice that has been specifically written for health professionals.

How supplied

Adbry

• 150 mg/mL per syringe, x 2
• Rx only
• For Subcutaneous Use Only
• Two 1-mL single-dose prefilled syringes equal 300 mg
• Carton contains:

• • Two 1-mL single-dose prefilled syringes with the needle guard
  • Prescribing Information
  • Instructions for Use and Patient Information

 

Adbry

• 150 mg/mL per syringe, x 4
• Rx only
• For Subcutaneous Use Only
• Four 1-mL single-dose prefilled syringes equal 600 mg
• Multipack contains:

• • Two cartons
  • Each carton contains two 1-mL single-dose prefilled syringes
    with needle guard which equal 300 mg

Additional details

Always consult your physician to confirm that the information provided on this page is applicable to your specific situation.